Drug Trial Radar · NCT06012708
Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713
Last checked: Nov 19, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Sep 11, 2023
Primary completion
Nov 5, 2024
Study completion Dec 16, 2024
Sponsor
- Lead sponsor
- New Cancer Cure-Bio Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of the combination therapy of KN510 and KN713 and determine the MTD and RP2D in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
KN510 60mg/day + KN713 60mg/dayDrug
Once daily with 28 days (4 weeks) as one cycle.
KN510 120mg/day + KN713 60mg/dayDrug
Once daily with 28 days (4 weeks) as one cycle.
KN510 120mg/day + KN713 90mg/dayDrug
Once daily with 28 days (4 weeks) as one cycle.
KN510 120mg/day + KN713 120mg/dayDrug
Once daily with 28 days (4 weeks) as one cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT(dose limiting toxicity)Time frame: Until 28 days from the first IP administration
- AEs(Adverse Events)Time frame: Through study completion, an average of 5 months
- Laboratory testsTime frame: Through study completion, an average of 5 months
- Vital signsTime frame: Through study completion, an average of 5 months
- ECG(Electrocardiogram)Time frame: Through study completion, an average of 5 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Cancer Center
Goyang-si, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.